SC Ropharma (BSE:RPH) EBITDA Margin %: 4.67% (As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSE:RPH SC Ropharma SA BSE:RPH
66 GF Score
Price lei0.20
View Full Analysis

What is SC Ropharma EBITDA Margin %?

SC Ropharma BSE:RPH 66 EBITDA Margin % is 4.67% as of Dec. 2024. GuruFocus rates BSE:RPH with a GF Score™ of 66/100.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. SC Ropharma's EBITDA for the six months ended in Dec. 2024 was lei30 Mil. SC Ropharma's Revenue for the six months ended in Dec. 2024 was lei632 Mil. Therefore, SC Ropharma's EBITDA margin for the quarter that ended in Dec. 2024 was 4.67%.

SC Ropharma  (BSE:RPH) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

SC Ropharma EBITDA Margin % Related Terms

SC Ropharma EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for SC Ropharma's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SC Ropharma EBITDA Margin % Chart

SC Ropharma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.55 5.14 4.11 4.56 4.71

SC Ropharma Semi-Annual Data
Dec13 Dec14 Dec15 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.19 4.93 4.20 4.74 4.67

SC Ropharma EBITDA Margin % Competitor Comparison

For the Pharmaceutical Retailers subindustry, SC Ropharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SC Ropharma EBITDA Margin % vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, SC Ropharma's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where SC Ropharma's EBITDA Margin % falls into.


BSE:RPH
66GF Score
SC Ropharma SA BSE:RPH
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SC Ropharma EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

SC Ropharma's EBITDA Margin % for the fiscal year that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=56.054/1191.066
=4.71 %

SC Ropharma's EBITDA Margin % for the quarter that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=29.548/632.353
=4.67 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 4.67% mean?
SC Ropharma (BSE:RPH) has a EBITDA Margin % of 4.67% as of Dec. 2024. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on SC Ropharma and its competitors.
Is SC Ropharma's EBITDA Margin % too high?
SC Ropharma's current EBITDA Margin % is 4.67%. The Healthcare Providers & Services industry median EBITDA Margin % is 10.24. SC Ropharma's value of 4.67% is 54.4% below this industry median. Overall, SC Ropharma has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does SC Ropharma's EBITDA Margin % compare to competitors?
SC Ropharma's EBITDA Margin % of 4.67% can be compared against companies in the Healthcare Providers & Services industry. The industry median EBITDA Margin % is 10.24. SC Ropharma's value of 4.67% is 54.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.24, based on 664 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SC Ropharma's current EBITDA Margin % of 4.67% is 54.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on SC Ropharma and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SC Ropharma's current EBITDA Margin % is 4.67%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SC Ropharma stock overvalued right now?
SC Ropharma (BSE:RPH) has a current EBITDA Margin % of 4.67%. The current EBITDA Margin % is 4.67% and 54.4% below the Healthcare Providers & Services industry median of 10.24. SC Ropharma's overall GF Score™ is 66/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For SC Ropharma (BSE:RPH), the current EBITDA Margin % is 4.67% as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SC Ropharma Business Description

Address Strada Iuliu Maniu Nr. 55, ETAJ 1, Brasow, ROU, 500091
SC Ropharma SA is engaged in the production, distribution, and Retail sale of pharmaceutical products in specialized stores. Its product portfolio comprises over 50 products in the form of tablets, powders, capsules, and syrups covering 21 therapeutic areas.
66GF Score

Get the complete analysis for BSE:RPH

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

lei0.20
Price